Management of Heart Failure by NYHA Functional Class

Introduction to NYHA Classification

The American College of Cardiology and American Heart Association staging system should be used in conjunction with the NYHA functional classification, as the latter is a subjective assessment that grades symptom severity but does not replace the former 1, 3

The American Heart Association recommends that all patients with heart failure and reduced ejection fraction (HFrEF, LVEF ≤35-40%) should receive guideline-directed medical therapy with ACE inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists regardless of NYHA class, as these therapies provide similar relative mortality reductions across all functional classes 1, 2
The European Society of Cardiology suggests that ACE inhibitors or ARBs should be initiated in all patients with HFrEF regardless of NYHA class, with a relative mortality reduction of 0.90 for NYHA I/II vs 0.88 for NYHA III/IV 1, 4
The American College of Cardiology recommends that beta-blockers are essential for all NYHA classes with similar relative benefit, though absolute benefit increases with higher NYHA class 1, 4
The American Heart Association recommends that mineralocorticoid receptor antagonists (MRAs) provide consistent relative mortality reduction across NYHA classes, and should be used in patients with NYHA class II-IV symptoms 1, 2

The American College of Cardiology and American Heart Association suggest that cardiac resynchronization therapy (CRT) provides similar relative mortality reduction across NYHA classes, and should be considered for patients with LVEF ≤35%, QRS duration ≥120-150 ms, and NYHA class II-IV symptoms 1, 2

The American Heart Association recommends that patients with NYHA class I (asymptomatic) should focus on optimizing guideline-directed medical therapy to prevent progression, and that these patients still have measurable mortality risk despite absence of symptoms 1, 2
The European Society of Cardiology suggests that patients with NYHA class II (mild symptoms) should initiate all guideline-directed medical therapies aggressively, and that consider ICD if LVEF ≤35% and life expectancy >1 year 1, 2
The American College of Cardiology recommends that patients with NYHA class IV (severe symptoms at rest) corresponds to ACC/AHA Stage D (advanced heart failure), and requires evaluation for advanced therapies including mechanical circulatory support, cardiac transplantation, or palliative care 1, 3

The American Heart Association suggests that NYHA class should be reassessed after each treatment adjustment throughout the continuum of care, recognizing that it can change rapidly, and that supplement NYHA classification with objective measures such as NT-proBNP levels, 6-minute walk distance, quality of life scores, and cardiopulmonary exercise testing when available 2, 3